Comparison of clinical outcomes between Magmaris and Orsiro drug eluting stent at 12 months: Pooled patient level analysis from BIOSOLVE II-III and BIOFLOW II trials.

Hideo-Kajita, Alexandre; Garcia-Garcia, Hector M; Kolm, Paul; Azizi, Viana; Ozaki, Yuichi; Dan, Kazuhiro; Ince, Hüseyin; Kische, Stephan; Abizaid, Alexandre; Töelg, Ralph; Lemos, Pedro Alves; Van Mieghem, Nicolas M; Verheye, Stefan; von Birgelen, Clemens; Christiansen, Evald Høj; Wijns, William; Lefèvre, Thierry; Windecker, Stephan; Waksman, Ron and Haude, Michael (2020). Comparison of clinical outcomes between Magmaris and Orsiro drug eluting stent at 12 months: Pooled patient level analysis from BIOSOLVE II-III and BIOFLOW II trials. International journal of cardiology, 300, pp. 60-65. Elsevier 10.1016/j.ijcard.2019.11.003

Text Comparison of clinical outcomes between Magmaris and Orsiro drug eluting stent at 12 months.pdf - Published Version Restricted to registered users only Available under License Publisher holds Copyright. Download (398kB) | Request a copy

BACKGROUND

The aim of this study was to compare the 12-month clinical outcomes of patients treated with Magmaris or Orsiro. Second generation drug-eluting absorbable metal scaffold Magmaris (Dreams 2G) has proved to be safe and effective in the BIOSOLVE-II study. Similarly, biodegradable polymer sirolimus-eluting stent, Orsiro has shown notable clinical results even in all-comer populations.

METHODS

Magmaris group patients were taken from the BIOSOLVE-II and BIOSOLVE-III trials, while the patients from Orsiro group were enrolled in BIOFLOW-II trial. The primary outcome was explored using a time-to-event assessment of the unadjusted clinical outcomes for target lesion failure (TLF) at 12 months, followed by a multivariate analysis adjusting for all the significantly different covariates between the groups.

RESULTS

The study population consisted of 482 patients (521 lesions), 184 patients (189 lesions) in Magmaris group and 298 patients (332 lesions) in Orsiro group. The mean age was 65.5 ± 10.8 and 62.7 ± 10.4 years in Magmaris and Orsiro groups, respectively (p = 0.005). Magmaris and Orsiro unadjusted TLF rates were 6.0 and 6.4% with no significant difference between the groups (p = 0.869). In the multivariate analysis, there were no meaningful differences between Magmaris and Orsiro groups. Finally, none of the groups presented device thrombosis cases at 12 months.

CONCLUSION

At 12 months there were no significant differences between Magmaris and Orsiro groups neither in the unadjusted assessment nor in the multivariate analysis for target lesion failure. These results should be taken as hypothesis generating and may warrant a head to head comparison on a randomized fashion.

Interest & Impact

Downloads

1 since deposited on 29 Jan 2020
0 in the past 12 months

Citations

5 Citations in Web of Science ®
6 Citations in Scopus

Search

in Google Scholar™

Services

Actions (login required)

Edit item

Actions (login required)

Edit item